Free Trial
NASDAQ:SXTP

60 Degrees Pharmaceuticals Q2 2024 Earnings Report

60 Degrees Pharmaceuticals logo
$1.39 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$1.39 0.00 (0.00%)
As of 08:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

60 Degrees Pharmaceuticals EPS Results

Actual EPS
-$84.60
Consensus EPS
-$55.80
Beat/Miss
Missed by -$28.80
One Year Ago EPS
N/A

60 Degrees Pharmaceuticals Revenue Results

Actual Revenue
$0.13 million
Expected Revenue
$0.11 million
Beat/Miss
Beat by +$20.00 thousand
YoY Revenue Growth
N/A

60 Degrees Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
TAS
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
7:00AM ET

60 Degrees Pharmaceuticals Earnings Headlines

I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement.tc pixel
60 Degrees Pharmaceuticals Announces 2025 Annual Results
See More 60 Degrees Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 60 Degrees Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 60 Degrees Pharmaceuticals and other key companies, straight to your email.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals (NASDAQ:SXTP), Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

View 60 Degrees Pharmaceuticals Profile